Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose bilateral aflibercept PK in DME or nAMD
2024-511665-11-00Phase 4Completed
- Sponsor
- Bayer
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME) and exudative macular degeneration, sponsored by Bayer. Primary endpoint: Maximum observed concentration (Cmax) of free aflibercept. Started Aug 2024; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)exudative macular degeneration
Beyond the preview
Go deeper on 2024-511665-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511665-11-00.